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Abstract
Public health surveillance is the ongoing collection, analysis and dissemination of health related 
data to provide information that can be used to monitor and improve the health of populations. 
Such surveillance systems can be established in many settings to study a variety of populations 
and conditions. The most effective systems are designed around specific, well-defined objectives, 
collect data in a standardized fashion, analyze the data frequently and disseminate the results to 
those who need to know the information.
Surveillance has been used to determine the occurrence rates of hemophilia and to characterize the 
population affected by this rare but potentially serious congenital disorder. Data from surveillance 
systems have been used to identify risk factors for complications that, once identified, have been 
modified through public health interventions. The effectiveness of these interventions can be 
assessed by continued surveillance, thereby assuring improvement in care of people affected by 
hemophilia around the world.
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Public health surveillance is traditionally defined as the ongoing systematic collection, 
analysis, and interpretation of health data, essential to the planning, implementation, and 
evaluation of public health practice, closely integrated to the dissemination of these data to 
those who need to know and linked to prevention and control [1].
The components of public health surveillance are ongoing data collection, regular and 
frequent data analysis and the provision of the results of these analyses to those who need to 
know. The data collected in such systems typically include demographic, socioeconomic and 
clinical characteristics of the population under surveillance, data on key outcomes such as 
disease complications and mortality, and data on potentially mitigating or aggravating 
behaviors or co-morbid conditions referred to as risk factors.
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Data can be collected from a variety of sources. For example, health data can be collected as 
part of surveys that can be population-based (i.e., designed to collect data from populations 
that are regionally or nationally representative) or they may be healthcare provider-based 
(i.e., designed to collect data from populations receiving health care services). For example, 
sentinel surveillance systems have been established in health care sites such as hospitals, 
clinics or care providers’ offices to monitor key health events such as cases of influenza or 
cancer. The main purpose of such provider-based surveillance systems is to obtain timely 
information on changes in the occurrence of a disease or condition that can inform 
preventive public health activities.
Data can also be collected for a wide variety of purposes using a registry. There are different 
types of registries including patient organization, medical and health ministry registries. 
Because patient organization registries typically have a minimal amount of health-related 
data they are generally more suited to facilitating communication and the distribution of 
educational material. Health ministry registries tend to be more public health oriented and 
national in scope. Because most are designed to be representative of the entire population 
these registries are the best sources of data for common diseases and conditions. People with 
rare diseases or conditions (generally defined in the U.S. as affecting fewer than 200,000 
individuals) are under-represented in these national databases. Medical registries are 
designed to collect information about a disease such as the occurrence, type, extent and the 
treatment provided and can be very useful for public health surveillance of rare conditions. 
Data from medical registries can be used not only to monitor disease trends over time and 
determine disease patterns in various populations but can also be used to guide planning and 
evaluation of disease control programs (e.g., determine whether prevention, screening, and 
treatment efforts are making a difference), help set priorities for allocating health resources 
and advance clinical, epidemiologic, and health services research in these disorders.
Data collection is instrumental to any surveillance system and it is important that efforts to 
collect data follow several key principles. First and foremost there must be clearly defined 
objectives for the surveillance which will in large part direct the choice of data elements. 
Measurement standards are critical and case definitions must be clear and, for some systems, 
diagnostic data may be required to validate events. Standardization of the data collection is 
essential for comparing population groups, geographic areas, or trends over long periods of 
time. All data elements should be clearly defined and should be easily available to the 
individuals assigned to collect them. Emphasis should be placed on collecting the minimum 
amount of data required to meet the surveillance objectives. Excessively large and complex 
data collection tools can substantially increase the burden of data collection which may 
adversely affect both the amount and quality of the data collected.
Also critical is the identification of the proper target population and choice of an adequate 
sampling strategy if the data are to be representative. Data should be gathered using an 
appropriate information gathering style (e.g., patient interview, clinical record review) such 
that the responses will most likely be valid and the data reliably reflect the true status of the 
condition under study. In all cases it is extremely important to apply ethical principles 
during the collection of data and to respect the privacy of the individuals under surveillance. 
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Laws and regulations concerning the confidentiality of data collected are universally 
available and should be adhered to as a matter of standard practice.
Once the data have been collected it is important to have secure database systems in place 
along with proper data management and quality control procedures. Data should be 
periodically evaluated for accuracy, consistency and completeness using standard data 
management procedures. Systems and procedures should be in place to protect data integrity 
as well as safety and security from natural disasters, computer virus attack, theft and other 
threats.
The analyses of surveillance data most often include cross-sectional descriptions of the 
population, outcomes and risk factors which can be further analyzed for trends over time. 
These kinds of analyses are useful for estimating the burden of the disease in the population, 
determining whether this burden is increasing or decreasing in the population as well as 
making assessments about whether certain segments of the population are more at risk for 
the disorder or its complications (so-called high-risk or target populations).
The results of these analyses should be shared widely not only with the public and 
healthcare workers but also with public health authorities and local and national 
governments and policy makers. More sophisticated analyses of these data can be used to 
look for associations between disease outcomes and risk factors. Such associations can 
provide the basis for the development of interventions designed to decrease the risk of 
complications or perhaps lessen spread of communicable disease. Once developed, the 
effectiveness of interventions implemented in the population can be assessed by continued 
disease surveillance and monitoring.
Surveillance and hemophilia
Surveillance has been used to address issues of great importance to the hemophilia 
population of the United States and around the world. In the U.S., the Centers for Disease 
Control and Prevention (CDC) working with the health departments of six states sponsored 
the Hemophilia Surveillance System (HSS). The purpose of this population-based system 
was to identify all people with hemophilia living in those states and collect detailed 
information about their demographic, clinical and health care characteristics from medical 
records. Data collected on over 3,000 males with hemophilia over a six-year period (1993–
1998) were used to describe occurrence rates and to study complications and outcomes of 
care [2].
A network of hemophilia treatment centers (HTCs) was developed in 1975 with federal 
funding to provide comprehensive multidisciplinary care to people with hemophilia in the 
U.S. [3]. Data from the HSS showed that about 70% of all people with hemophilia were 
receiving some care from these centers in the early 1990s. More importantly, when 
outcomes were compared, it was found that those who had received at least some care from 
an HTC over a 3-year period were 40% less likely to die [4] and a similar proportion were 
less likely to be hospitalized for a bleeding complication [5]. Subsequently, data from the 
HSS were used to study other complications of hemophilia including intracranial 
hemorrhage [6], heart disease [7] and renal disease [8]. HSS data were also used to 
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determine the extent of infections with hepatitis and the human immunodeficiency virus in 
the hemophilia population as a result of contaminated treatment products [9].
Based upon the request of the hemophilia community to provide a sensitive surveillance 
system that could monitor the population and protect it from further infectious disease 
threats to treatment products, a new surveillance system was established in the US HTC 
network in 1998 called the Universal Data Collection (UDC) system [10]. Patients receiving 
care in HTCs could volunteer to participate in UDC each year and provide a blood specimen 
that was tested for known viruses and stored for future blood product safety investigations. 
The results of data from this surveillance have provided assurance to the community that 
current treatment products are very safe [11]. Using other data collected as part of UDC, 
researchers have contributed to the knowledge about other aspects of hemophilia including 
joint disease [12], inhibitors [13], educational achievement [14] and physical functioning 
[15].
Since 1998, the World Federation of Hemophilia has conducted surveillance by means of an 
annual global survey [16]. Data are collected from over 100 countries on various aspects of 
hemophilia and other blood disorders using a standardized data collection form. Data from 
these surveys have been used to estimate the world hemophilia population and to examine 
the effects of comprehensive hemophilia care throughout the world. For example, using 
survey data combined with economic data Evatt and Robillard [17] were able to show that 
even in the poorest of countries the organization of hemophilia care resulted in greater 
patient survival.
It should be noted that the success of the CDC and WFH surveillance systems in meeting the 
needs of the hemophilia community required a substantial commitment from governments, 
healthcare providers and people with hemophilia receiving care in HTCs. Government 
participation is often needed to provide the organizational and capacity infrastructure 
necessary to support national and regional surveillance activities. Healthcare providers have 
important roles not only in patient recruitment but also in data collection and assuring the 
safety of participants and the privacy and security of the collected patient data. Finally, it is 
critical that participants in any surveillance understand what is being asked of them and how 
their individual data will be used. In addition, it is important that patients understand that 
surveillance is an ongoing process and its full impact often requires a substantial period of 
time to be fully realized.
Conclusion
Data collected as part of a public health surveillance system can be used to estimate the 
magnitude of a problem, identify groups at higher risk of having poorer outcomes, examine 
relationships between risk factors and outcomes, develop interventions and with continued 
monitoring assess the effectiveness of the interventions to modify the complications or 
outcomes.
The results of analyses from surveillance data can be useful for many purposes including 
health care and patient advocacy, providing a basis for priority setting and allocation of 
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health care resources, ensuring the availability of better data on population health and 
supporting medical care quality assurance and quality improvement efforts.
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